|0.5 mg/mL of rabbit anti-CD82 monoclonal antibody (in PBS, pH 7.4). Dilute to a working concentration of 2 μg/mL in CBS before coating. (Catalog: # 12275-R071)|
|0.17 mg/mL rabbit anti-CD82 monoclonal antibody conjugated to horseradish-peroxidase (HRP) (in PBS, 67 % HRP-Protector, pH 7.4). Dilute to working concentration of 0.25 μg/mL in detection antibody dilution buffer before use. (Catalog: # 12275-R072)|
|Each vial contains 47 ng of recombinant CD82. Reconstitute with 1 mL detection antibody dilution buffer. After reconstitution, store at -20℃ to -80℃ in a manual defrost freezer. A seven-point standard curve using 2-fold serial dilutions in sample dilution buffer, and a high standard of 5 ng/mL is recommended.|
|The minimum detectable dose of Human CD82 / KAI-1 was determined to be approximately 78 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard.|
|The Human CD82 / KAI-1 ELISA Pair Set is for the quantitative determination of Human CD82 / KAI-1.|
This ELISA Pair Set contains the basic components required for the development of sandwich ELISAs.
The Sino Biological ELISA Pair Set is a solid phase sandwich ELISA (Enzyme-Linked Immunosorbent Assay). It utilizes a monoclonal antibody specific for CD82 / KAI-1 coated on a 96-well plate. Standards and samples are added to the wells, and any CD82 / KAI-1 present binds to the immobilized antibody. The wells are washed and a horseradish peroxidase conjugated rabbit anti-CD82 / KAI-1 monoclonal antibody is then added, producing an antibody-antigen-antibody "sandwich". The wells are again washed and TMB substrate solution is loaded, which produces color in proportion to the amount of CD82 / KAI-1 present in the sample. To end the enzyme reaction, the stop solution is added and absorbances of the microwell are read at 450 nm.
CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.